A number of other equities research analysts have also issued reports on the stock. Credit Suisse Group began coverage on shares of AveXis in a research note on Wednesday, January 17th. They set an outperform rating and a $134.00 target price for the company. Royal Bank of Canada reissued a hold rating and set a $92.00 target price on shares of AveXis in a research note on Tuesday, January 9th. Zacks Investment Research raised shares of AveXis from a sell rating to a hold rating in a research note on Tuesday, January 9th. Canaccord Genuity set a $110.00 target price on shares of AveXis and gave the company a hold rating in a research note on Friday, January 5th. Finally, Chardan Capital reissued a buy rating and set a $135.00 target price on shares of AveXis in a research note on Friday, January 5th. Three analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $113.89.
AveXis (AVXS) traded down $1.92 during midday trading on Thursday, reaching $108.25. 777,100 shares of the company’s stock traded hands, compared to its average volume of 788,531. The stock has a market cap of $3,885.52, a PE ratio of -19.40 and a beta of 2.46. AveXis has a 12-month low of $50.56 and a 12-month high of $119.00.
In other AveXis news, VP Andrew F. Knudten sold 2,000 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $94.48, for a total transaction of $188,960.00. Following the completion of the transaction, the vice president now owns 7,000 shares of the company’s stock, valued at approximately $661,360. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Brian K. Kaspar sold 15,000 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $101.23, for a total transaction of $1,518,450.00. Following the transaction, the insider now directly owns 1,841,019 shares of the company’s stock, valued at approximately $186,366,353.37. The disclosure for this sale can be found here. In the last ninety days, insiders sold 57,340 shares of company stock valued at $5,851,445. 18.60% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Amalgamated Bank lifted its position in AveXis by 19.6% during the 3rd quarter. Amalgamated Bank now owns 3,187 shares of the company’s stock worth $308,000 after acquiring an additional 523 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in AveXis by 2.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 20,943 shares of the company’s stock worth $1,721,000 after acquiring an additional 598 shares during the last quarter. ProShare Advisors LLC lifted its position in AveXis by 6.4% during the 2nd quarter. ProShare Advisors LLC now owns 16,427 shares of the company’s stock worth $1,350,000 after acquiring an additional 985 shares during the last quarter. Strs Ohio acquired a new position in AveXis during the 3rd quarter worth $116,000. Finally, Schwab Charles Investment Management Inc. lifted its position in AveXis by 1.3% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 109,902 shares of the company’s stock worth $12,163,000 after acquiring an additional 1,389 shares during the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.